PE20010753A1 - DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a - Google Patents
DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2aInfo
- Publication number
- PE20010753A1 PE20010753A1 PE2000001099A PE0010992000A PE20010753A1 PE 20010753 A1 PE20010753 A1 PE 20010753A1 PE 2000001099 A PE2000001099 A PE 2000001099A PE 0010992000 A PE0010992000 A PE 0010992000A PE 20010753 A1 PE20010753 A1 PE 20010753A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- phenyl
- cycloalkyl
- amino
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
Abstract
SE REFIERE A DERIVADOS DE N-[(PURIN-2-IL)METIL]SULFONAMIDA DE FORMULA I, DONDE R1 ES H, ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO CON FENILO, NAFTILO; A ES UN ENLACE, ALQUILENO C1-C3, R2 ES i)H, ALQUILO C1-C6, CICLOALQUILO C3-C7, ENTRE OTROS; ii)CUANDO A ES ALQUILENO C2-C3, NR8R9, OR3, COOR3, ENTRE OTROS; iii)HETEROCICLO DE 4-11 MIEMBROS; R3 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C7, FENILO; R4 ES ALQUILO C1-C6, CICLOALQUILO C3-C7, FENILO; R5 ES H, ALQUILO C1-C6, FENILO, ENTRE OTROS; R6 ES ALQUILO C1-C6, FENILO, NAFTILO, HET; m ES 0-2; R7 ES METILO, ETILO, CICLOPROPILO; R8 Y R9 JUNTO A N FORMAN AZETIDINILO, PIRROLIDINILO, ENTRE OTROS; O R8 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C8. SON COMPUESTO PREFERIDOS (2S,3S,4R,5R)-5-{2-{[(BENCILSULFONIL)AMINO]METIL}-6-[(2,2-DIFENILETIL)AMINO]-9H-PURIN-9-IL}-N-ETIL-3,4-DIHIDROXITETRAHIDRO-2-FURANOCARBOXAMIDA, (2S,3S,4R,5R)-5-[6-[(2,2-DIFENILETIL)AMINO]-2-{[(PROPILSULFONIL)AMINO]METIL}-9H-PURIN-9-IL}-N-ETIL-3,4-DIHIDROXITETRAHIDRO-2-FURANOCARBOXAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION, A COMPUESTOS INTERMEDIOS. EL COMPUESTO I ES UN AGONISTA DEL RECEPTOR DE ADENOSINA A2a Y PUEDE SER UTIL PARA EL TRATAMIENTO DE UN ENFERMEDAD RESPIRATORIA, SINDROME DE INSUFICIENCIA RESPIRATORIA, BRONQUITIS, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA, HIPERTENSION, DISFUNCION ERECTIL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9924361.0A GB9924361D0 (en) | 1999-10-14 | 1999-10-14 | Purine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010753A1 true PE20010753A1 (es) | 2001-07-17 |
Family
ID=10862758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000001099A PE20010753A1 (es) | 1999-10-14 | 2000-10-13 | DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a |
Country Status (43)
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0003960D0 (en) | 2000-02-18 | 2000-04-12 | Pfizer Ltd | Purine derivatives |
| GB0015727D0 (en) * | 2000-06-27 | 2000-08-16 | Pfizer Ltd | Purine derivatives |
| US6921753B2 (en) | 2000-06-27 | 2005-07-26 | Pfizer Inc | Purine derivatives |
| GB0022695D0 (en) | 2000-09-15 | 2000-11-01 | Pfizer Ltd | Purine Derivatives |
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| US20050033044A1 (en) * | 2003-05-19 | 2005-02-10 | Bristol-Myers Squibb Pharma Company | Methods for preparing 2-alkynyladenosine derivatives |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| ES2563952T3 (es) | 2004-03-26 | 2016-03-16 | Sumitomo Dainippon Pharma Co., Ltd. | Compuesto de 8-oxoadenina 9-sustituido |
| TWI346109B (en) * | 2004-04-30 | 2011-08-01 | Otsuka Pharma Co Ltd | 4-amino-5-cyanopyrimidine derivatives |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| WO2005117910A2 (en) * | 2004-05-26 | 2005-12-15 | Inotek Pharmaceuticals Corporation | Purine derivatives as adenosine a1 receptor agonists and methods of use thereof |
| KR20070058626A (ko) * | 2004-09-20 | 2007-06-08 | 이노텍 파마슈티컬스 코포레이션 | 퓨린 유도체 및 이것의 사용 방법 |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| EP1957530A2 (en) | 2005-10-21 | 2008-08-20 | Novartis AG | Human antibodies against il13 and therapeutic uses |
| NZ568392A (en) * | 2005-11-30 | 2011-07-29 | Inotek Pharmaceuticals Corp | Purine derivatives and methods of use thereof |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| PL2013211T3 (pl) * | 2006-04-21 | 2012-08-31 | Novartis Ag | Pochodne puryny do zastosowania jako agoniści receptora adenozyny A2A |
| JP2009542645A (ja) | 2006-07-05 | 2009-12-03 | アストラゼネカ・アクチエボラーグ | Ｔｌｒ７のモジュレーターとして作用する８−オキソアデニン誘導体 |
| ATE502943T1 (de) | 2006-09-29 | 2011-04-15 | Novartis Ag | Pyrazolopyrimidine als pi3k-lipidkinasehemmer |
| BRPI0718266A2 (pt) | 2006-10-30 | 2014-01-07 | Novartis Ag | Compostos heterocíclicos como agentes anti-inflamatórios. |
| TW200831105A (en) * | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
| EP2118106A1 (en) * | 2007-03-02 | 2009-11-18 | Glaxo Group Limited | Purines as cysteine protease inhibitors |
| DK2132209T3 (da) * | 2007-03-19 | 2014-04-14 | Astrazeneca Ab | 9-substituerede 8-oxo-adeninforbindelser som modulatorer af tlr7 (toll-like receptor 7) |
| WO2008114006A1 (en) * | 2007-03-19 | 2008-09-25 | Astrazeneca Ab | 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators |
| PE20081887A1 (es) * | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | Nuevo compuesto de adenina |
| EP2138497A4 (en) | 2007-03-20 | 2012-01-04 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
| CN101687867B (zh) * | 2007-05-08 | 2013-10-02 | 阿斯利康(瑞典)有限公司 | 具有免疫调节性质的咪唑并喹啉 |
| PE20091156A1 (es) | 2007-12-17 | 2009-09-03 | Astrazeneca Ab | Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo |
| US8431578B2 (en) | 2008-01-11 | 2013-04-30 | Novartis Ag | Organic compounds |
| US8865896B2 (en) | 2008-01-17 | 2014-10-21 | Astrazeneca Aktiebolag | Method for preparing adenine compound |
| US20110054168A1 (en) * | 2008-01-17 | 2011-03-03 | Ayumu Kurimoto | Method for preparing adenine compound |
| PT2391366E (pt) | 2009-01-29 | 2013-02-05 | Novartis Ag | Benzimidazoles substituídos para o tratamento de astrocitomas |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| BR112012003262A8 (pt) | 2009-08-12 | 2016-05-17 | Novartis Ag | compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação |
| PE20121148A1 (es) | 2009-08-17 | 2012-09-07 | Intellikine Llc | Compuestos heterociclicos y usos de los mismos |
| KR20120089463A (ko) | 2009-08-20 | 2012-08-10 | 노파르티스 아게 | 헤테로시클릭 옥심 화합물 |
| WO2011068233A1 (en) * | 2009-12-03 | 2011-06-09 | Dainippon Sumitomo Pharma Co., Ltd. | Imidazoquinolines which act via toll - like receptors (tlr) |
| LT2523669T (lt) | 2010-01-11 | 2017-04-25 | Inotek Pharmaceuticals Corporation | Akispūdžio mažinimo būdas, derinys ir rinkinys |
| WO2011119969A1 (en) | 2010-03-26 | 2011-09-29 | Inotek Pharmaceuticals Corporation | Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| CN103370317B (zh) | 2010-12-16 | 2015-10-07 | 阿斯利康(瑞典)有限公司 | 可用于治疗的咪唑并[4,5-c]喹啉-1-基衍生物 |
| DK2651943T3 (en) | 2010-12-17 | 2017-06-06 | Sumitomo Dainippon Pharma Co Ltd | purine derivatives |
| EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| MA34969B1 (fr) | 2011-02-25 | 2014-03-01 | Irm Llc | Composes et compositions en tant qu inibiteurs de trk |
| AU2012310168B2 (en) | 2011-09-15 | 2015-07-16 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
| CA2856803A1 (en) | 2011-11-23 | 2013-05-30 | Intellikine, Llc | Enhanced treatment regimens using mtor inhibitors |
| RS56150B1 (sr) | 2012-01-26 | 2017-11-30 | Inotek Pharmaceuticals Corp | Anhidrovani polimorfi (2r,3s,4r,5r)-5-(6-(ciklopentilamino)-9h-purin-9-yl)-3,4-dihidroksitetrahidrofuran-2-yl)} metil-nitrata i postupak njegove pripreme |
| JP2015512425A (ja) | 2012-04-03 | 2015-04-27 | ノバルティス アーゲー | チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用 |
| KR20150139501A (ko) | 2013-03-15 | 2015-12-11 | 이노텍 파마슈티컬스 코포레이션 | 안과용 제형 |
| CA2906542A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
| WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| JP6526789B2 (ja) | 2014-07-31 | 2019-06-05 | ノバルティス アーゲー | 組み合わせ療法 |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5536419A (en) * | 1978-09-08 | 1980-03-14 | Yamasa Shoyu Co Ltd | 2-substituted adenosine derivative and its preparation |
| WO1988003147A1 (en) * | 1986-10-31 | 1988-05-05 | Warner-Lambert Company | Selected n6-substituted adenosines having selective a2 binding activity |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5877180A (en) * | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
| GB9414193D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| CA2347512C (en) * | 1998-10-16 | 2005-12-06 | Pfizer Inc. | Adenine derivatives |
| GB9913932D0 (en) | 1999-06-15 | 1999-08-18 | Pfizer Ltd | Purine derivatives |
-
1999
- 1999-10-14 GB GBGB9924361.0A patent/GB9924361D0/en not_active Ceased
-
2000
- 2000-09-26 PA PA20008503601A patent/PA8503601A1/es unknown
- 2000-10-06 PL PL00354880A patent/PL354880A1/xx not_active Application Discontinuation
- 2000-10-06 GE GE4727A patent/GEP20043324B/en unknown
- 2000-10-06 MX MXPA02003750A patent/MXPA02003750A/es active IP Right Grant
- 2000-10-06 CN CNB008141762A patent/CN1166678C/zh not_active Expired - Fee Related
- 2000-10-06 SK SK474-2002A patent/SK4742002A3/sk unknown
- 2000-10-06 AT AT00962773T patent/ATE321065T1/de not_active IP Right Cessation
- 2000-10-06 NZ NZ517294A patent/NZ517294A/en unknown
- 2000-10-06 IL IL14833100A patent/IL148331A0/xx unknown
- 2000-10-06 DE DE60026861T patent/DE60026861T2/de not_active Expired - Fee Related
- 2000-10-06 EE EEP200200194A patent/EE200200194A/xx unknown
- 2000-10-06 WO PCT/IB2000/001446 patent/WO2001027131A1/en active IP Right Grant
- 2000-10-06 CZ CZ20021179A patent/CZ20021179A3/cs unknown
- 2000-10-06 OA OA1200200103A patent/OA12060A/en unknown
- 2000-10-06 HU HU0203485A patent/HUP0203485A3/hu unknown
- 2000-10-06 AP APAP/P/2002/002480A patent/AP2002002480A0/en unknown
- 2000-10-06 AU AU74412/00A patent/AU771531B2/en not_active Ceased
- 2000-10-06 CA CA002387533A patent/CA2387533C/en not_active Expired - Fee Related
- 2000-10-06 BR BR0014760-5A patent/BR0014760A/pt not_active IP Right Cessation
- 2000-10-06 EA EA200200360A patent/EA004985B1/ru not_active IP Right Cessation
- 2000-10-06 EP EP00962773A patent/EP1220862B1/en not_active Expired - Lifetime
- 2000-10-06 JP JP2001530349A patent/JP3994008B2/ja not_active Expired - Fee Related
- 2000-10-06 KR KR1020027004766A patent/KR20030022758A/ko active IP Right Grant
- 2000-10-06 ES ES00962773T patent/ES2257317T3/es not_active Expired - Lifetime
- 2000-10-06 TR TR2002/01001T patent/TR200201001T2/xx unknown
- 2000-10-10 GT GT200000170A patent/GT200000170A/es unknown
- 2000-10-12 EC EC2000003713A patent/ECSP003713A/es unknown
- 2000-10-12 MY MYPI20004789A patent/MY141512A/en unknown
- 2000-10-12 GT GT200000173A patent/GT200000173A/es unknown
- 2000-10-12 CO CO00077983A patent/CO5261621A1/es not_active Application Discontinuation
- 2000-10-13 PE PE2000001099A patent/PE20010753A1/es not_active Application Discontinuation
- 2000-10-13 SV SV2000000199A patent/SV2002000199A/es unknown
- 2000-10-13 AR ARP000105422A patent/AR026052A1/es unknown
- 2000-10-13 TN TNTNSN00203A patent/TNSN00203A1/fr unknown
- 2000-10-16 US US09/688,497 patent/US6448236B1/en not_active Expired - Fee Related
-
2002
- 2002-02-26 IS IS6287A patent/IS6287A/is unknown
- 2002-03-11 CR CR6607A patent/CR6607A/es not_active Application Discontinuation
- 2002-04-02 BG BG106567A patent/BG106567A/xx unknown
- 2002-04-08 ZA ZA200202725A patent/ZA200202725B/en unknown
- 2002-04-09 MA MA26591A patent/MA26829A1/fr unknown
- 2002-04-12 HR HR20020325A patent/HRP20020325A2/xx not_active Application Discontinuation
- 2002-04-12 NO NO20021751A patent/NO20021751L/no not_active Application Discontinuation
-
2003
- 2003-01-07 HK HK03100163.8A patent/HK1047942B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010753A1 (es) | DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a | |
| PE20010755A1 (es) | DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a | |
| JP2010515750A5 (es) | ||
| PE20010430A1 (es) | DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a | |
| PE20121506A1 (es) | Compuestos triazolopiridinas como inhibidores de c-met | |
| PE20070189A1 (es) | COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA | |
| PE20060625A1 (es) | Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina | |
| RU2007147046A (ru) | Мочевинные активаторы глюкокиназы | |
| PE20051141A1 (es) | Inhibidores de la polimerasa viral | |
| EA200800477A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
| PE20110411A1 (es) | Imidazopiridazinacarbonitrilos como inhibidores de quinasa | |
| PE20120546A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR069740A1 (es) | Compuestos nucleosidos antivirales | |
| EA200200770A1 (ru) | Производные пурина | |
| PE20110835A1 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| PE20120655A1 (es) | Derivados de triazolopiridina como inhibidores de proteinas cinasas activadas por mitogeno p38 (map) | |
| PE20070002A1 (es) | Compuestos derivados de heteroaril como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo i | |
| RU2008110917A (ru) | ПРОИЗВОДНЫЕ 7-(2-АМИНО-1-ГИДРОКСИ-ЭТИЛ)-4-ГИДРОКСИБЕНЗОТИАЗОЛ-2(3Н)-ОНА В КАЧЕСТВЕ АГОНИСТОВ β2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ | |
| PE20070179A1 (es) | Derivados de purina como agonistas del receptor de adenosina a2 | |
| PE20061198A1 (es) | Derivados de pirazol como inhibidores de cdk y gsk | |
| PE20130385A1 (es) | Derivados del acido naft-2-ilacetico para tratar el sida | |
| PE20120814A1 (es) | Compuestos y composiciones como inhibidores de la proteina cinasa | |
| JP2004501930A5 (es) | ||
| PE20060383A1 (es) | Nuevos derivados amino de urea ciclicos como inhibidores de quinasa | |
| RU2008107727A (ru) | Макроциклические ингибиторы вируса гепатита с |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |